Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 159   

Articles published

MRK 59.55 -0.55 (-0.92%)
price chart
3 Reasons Merck & Co., Inc.'s Stock Could Fall
If you were lucky enough to time your purchase of Merck (NYSE: MRK ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater.
Related articles »  
Is it Time to Buy Merck & Co., Inc.'s Stock?
Investors in pharmaceutical giant Merck (NYSE: MRK ) have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and ...
Related articles »  
Is Merck & Co., Inc. A Leader In A Red Hot Market?
Merck & Co., Inc. (NYSE: MRK) stock has been on a steady incline for the most part since the 2009 bottom. With the stock now challenging 2007�2008 highs, will the underlying fundamentals be enough to incite an upside breakout?
Insider Selling: Kenneth C. Frazier Unloads 9814 Shares of Merck & Co ...  WKRB News
Related articles »  
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Merck (NYSE: MRK ) has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or unresectable ...
Merck Beats Bristol-Myers In Breakthrough Cancer Drug Race  Bidness ETC
FDA OKs Merck melanoma drug, 1st in its class  CNBC
Related articles »  
Bristol-Myers, Merck In Patent Battle To Take Lead In Immunotherapy Market
Merck & Co., Inc. (MRK) has been sued by Bristol-Myers Squibb Co (BMY) and Ono Pharmaceutical Co., Ltd. (Japan) (OPHLY) for patent infringement of Bristol-Myers' novel PD-1 inhibitor, Optivo.
Merck & Co., Inc. (NYSE:MRK) Dragged To Court On Immunotherapy Patent Issue  WallStreetPR
FDA OKs Merck drug, 1st in new cancer drug class  Casper Star-Tribune Online
Related articles »  
Merck & Co. Inc. (MRK) Tops DJIA Gainers for September 3
The Dow closed at 17,078.30 on Wednesday, which is a 0.06% move from yesterday's close. Merck & Co. Inc. led all gainers with a 1.15% jump.
Related articles »  
Oncothyreon And Merck Develop Tecemodite
Oncothyreon Inc. (ONTY) announced today that Merck KGaA's (MRK) biopharmaceutical business, Merck Serono, will be developing its antigen-specific cancer immunotherapy, tecemotide (previously known as Stimuvax).
Merck Discontinues Clinical Development Program of Tecemotide as a ...  PR Newswire India (press release)
Related articles »  
Bristol-Myers Squibb Co (BMY) Sues Merck & Co., Inc. (MRK) Over Cancer Drug ...
Bristol-Myers Squibb Co (NYSE:BMY) along with Ono Pharmaceutical launched a lawsuit against Merck & Co., Inc. (NYSE:MRK) last Thursday, claiming that the company's new cancer drug Keytruba (which was approved by the FDA the same day) violates ...
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog  NASDAQ
Related articles »  
3 Reasons Merck & Co., Inc.'s Stock Could Rise
For investors lucky enough to have jumped into Merck (NYSE: MRK ) in 2009 at the tail end of the Great Recession you've seen an appreciation in your shares of near 100%.
Related articles »  
Merck & Co. Inc. (MRK) Tops DJIA Gainers for August 22
The Dow closed at 17,001.20 on Friday, which is a -0.22% move from yesterday's close. Merck & Co. Inc. led all gainers with a 0.54% jump.